GSK presents new data from AReSVi-006 phase III trial of Arexvy

GSK announced new data from the AReSVi-006, Adult Respiratory Syncytial Virus, phase III trial evaluating the efficacy of a single dose of Arexvy against lower respiratory tract disease, LRTD, caused by respiratory syncytial virus, RSV in adults aged 60 years and older, including those at increased risk over three full RSV seasons. These data will be presented today at the CHEST 2024 Annual Meeting, organized by the American College of Chest Physicians. Today’s results indicate that after a single dose of GSK‘s RSV vaccine, cumulative efficacy over three full RSV seasons was clinically meaningful at 62.9% against RSV-LRTD and 67.4% against severe RSV-LRTD compared to placebo. In the third season, the vaccine’s efficacy was 48.0% against RSV-LRTD. These results include efficacy against different RSV subtypes, in adults with advancing age, and those with certain underlying medical conditions. Since RSV can exacerbate medical conditions and potentially lead to hospitalisations, cumulative efficacy over three RSV seasons has the potential for significant health impact. It has the potential to offer health care professionals flexibility to administer the vaccine year-round. Over time, revaccination is expected to be required to maintain an optimal level of protection.